Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Quanterix Corporation QTRX

Healthcare — Medical Devices
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.30
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — 1 — — 1 —
Sell — — — — — — — — — — — —
Insider Ownership
11.44%

Capital & Financial Ratios

Market Cap
145.45
Revenue
153.41
Net Income
(123.11)
Free Cash Flow
(81.68)
Net Debt
(93.53)
Current Ratio
3.40
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
0.95
P/B ratio
0.61
Past 5Y EPS Growth
9.19%
This Y EPS Growth
10.30%
Next Y EPS Growth
44.94%
Next 5Y EPS Growth
25.85%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 321.32 289.12 118.23 93.53
Receivables 25.41 32.14 29.97 22.35
Inventory 26.12 32.78 54.76 47.60
Other — — — —
382.10 363.59 212.26 171.05
2023 2024 2025 Q'26
Payables 5.05 6.95 13.57 8.89
ST’ Debt — — — —
Other — — — —
38.98 42.01 74.76 50.37
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 36.42 32.91 — —
—
’25 30.33 24.48 40.23 43.86
138.90
’24 32.07 34.38 35.81 35.16
137.42
’23 28.46 30.80 31.56 31.55
122.37
’22 29.55 23.50 26.65 25.82
105.52
’21 27.21 25.37 27.69 30.29
110.56
’20 15.73 13.13 31.39 26.13
86.38
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (18.11) (5.12) — —
—
’25 (13.89) (5.65) (41.25) (16.44)
(77.24)
’24 (20.16) (4.95) (5.75) (4.30)
(35.16)
’23 (9.82) 1.03 (3.87) (6.19)
(18.85)
’22 (21.69) (7.94) (14.55) (4.43)
(48.61)
’21 (14.09) (9.75) (13.78) (10.01)
(47.62)
’20 (13.18) (7.42) (7.42) 4.65
(23.36)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (18.19) (5.21) — —
—
’25 (15.14) (6.43) (41.93) (16.35)
(79.85)
’24 (20.67) (6.55) (6.60) (4.71)
(38.53)
’23 (9.96) 0.22 (4.80) (8.15)
(22.69)
’22 (23.09) (13.00) (18.22) (5.91)
(60.22)
’21 (14.17) (17.01) (17.60) (12.52)
(61.30)
’20 (13.60) (8.36) (8.21) 2.87
(27.29)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.37) (1.04) — —
—
’25 (0.53) (0.77) (0.73) (0.49)
(2.51)
’24 (0.26) (0.25) (0.22) (0.30)
(1.00)
’23 (0.16) (0.16) (0.21) (0.33)
(0.86)
’22 (0.49) (0.67) (0.95) (0.50)
(2.61)
’21 (0.29) (0.33) (0.43) (0.55)
(1.60)
’20 (0.39) (0.42) 0.07 (0.31)
(1.10)

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

3
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 6.31 10.02 9.87 4.05 — — —
Low Price
— ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 43.32 28.78 29.70 12.41 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 125 441 471 450 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.84 0.28 0.29 0.31 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 105.52 122.37 137.42 138.90 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 42.99% 60.66% 60.47% 46.77% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (99.41) (27.63) (38.10) (112.27) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (94.21%) (22.58%) (27.72%) (80.83%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (99.57) (28.35) (38.53) (107.15) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.41 7.64 6.46 23.60 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.85 3.26 3.58 3.26 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ (2.61) (0.86) (1.00) (2.51) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.31) (0.50) (0.92) (1.81) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.31) (0.10) (0.09) (0.06) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.63) (0.60) (1.00) (1.87) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.68 9.31 8.60 6.94 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 36.99 37.59 38.37 42.64 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.51 8.34 2.97 1.95 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.33 2.92 1.24 0.92 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.72 6.06 1.17 1.13 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.01) (32.69) (4.18) (1.97) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (48.61) (18.85) (35.16) (77.24) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (11.61) (3.84) (3.37) (2.61) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (60.22) (22.69) (38.53) (79.85) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 350.18 343.11 321.59 137.50 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 44.10 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (294.64) (321.32) (289.12) (118.23) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 357.93 349.96 330.04 295.73 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (21.30%) (6.58%) (9.23%) (25.97%) ‡‡‡‡‡ — —
ROA
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (102.95%) (100.39%) (80.37%) (44.21%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (24.93%) (8.01%) (11.33%) (34.25%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Quanterix Corporation (QTRX), a leader in ultrasensitive protein detection through its Simoa platform, boasts impressive revenue growth from $17.6 million in 2016 to $137.4 million in 2024 at over 30% CAGR, fueled by high-margin consumables and neurodegeneration research adoption. Gross margins have climbed to 60%, and a robust balance sheet with $289 million in cash provides a liquidity fortress amid biotech volatility. Recent insider buying frenzy—totaling nearly $3 million with no offsetting sells—signals confidence, aligning with analyst price targets implying 22-39% upside from current undervalued levels, down 94% from 2021 peaks.

Yet, deceleration looms: revenue growth slowed to 10-12% recently, with forecasts showing a 3% dip in 2025 before rebounding, while net losses balloon to $95 million next year despite margin gains. Past scars like a 73% workforce cut in 2022 highlight execution risks, competition in diagnostics, and macro headwinds in a high-rate environment. This contrarian dissection reveals a potential bargain or value trap—dive deeper to uncover if Simoa’s edge can deliver profitability and double the stock, or if it’s biotech graveyard fodder.

Read full commentary →

Quanterix Corporation (QTRX) Latest News

News by impact score

Fine-tune

17 Aug

4 transcript www.fool.com, 12:28 PM
Quanterix Corporation held its Q2 2026 earnings call to review financial results and business outlook. Earnings call delivers performance metrics and guidance that can shift investor sentiment and stock trajectory.

16 Aug

4 www.marketbeat.com, 2:02 PM
Quanterix is reshaping its sales strategy and targeting a Q4 FDA decision for its Alzheimer’s blood test. Sales strategy overhaul plus pending FDA decision on Alzheimer’s blood test signals major strategic and regulatory moves likely to alter company trajectory and investor sentiment.

12 Aug

3 , 9:13 AM
Quanterix earnings disrupt prior narratives while fair value estimates remain higher than current trading levels. Earnings releases produce moderate short-term shifts in sentiment and valuation views for Quanterix without fundamentally changing long-term trajectory.

10 Aug

4 transcript , 5:01 PM
Quanterix missed Q2 2026 revenue expectations and cut full-year guidance amid operational and market pressures. Revenue miss combined with lowered guidance directly weakens near-term financial outlook and investor sentiment.

4 investorshub.advfn.com, 11:04 AM
Quanterix cuts 2026 revenue outlook as commercial challenges delay cash-flow break-even. Revenue outlook cut and delayed break-even signal major commercial setbacks that will likely weigh on valuation and growth expectations.

3 transcript www.marketbeat.com, 11:04 AM
Quanterix Q2 earnings call highlighted financial results, revenue figures, operational updates and forward outlook for the company. Q2 earnings details can moderately shift investor views on Quanterix financial trajectory.

14 Jul

4 , 4:29 PM
Anthem Blue Cross and Blue Shield establishes commercial coverage for LucentAD Complete. Quanterix will present new data highlighting multi-analyte advantages. Major payer coverage expands market access for LucentAD Complete and supports revenue growth for Quanterix.

9 May

4 Simply Wall St., 12:16 PM
Tempus AI partners with Quanterix on new Alzheimer’s blood test alliance, expanding beyond oncology into neurodegenerative diagnostics using Quanterix's ultrasensitive Simoa technology. Alliance with major AI health data firm Tempus validates Quanterix's core technology and opens substantial new market in Alzheimer’s diagnostics.

7 May

4 transcript www.fool.com, 10:44 AM
Quanterix (QTRX) released Q1 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial performance, strategic initiatives, and guidance likely to significantly sway investor sentiment and stock trajectory.

3 app.moby.co, 8:30 AM
Quanterix Corporation released its Q1 2026 earnings call summary covering financial results and operational updates. Earnings call details typically influence near-term market sentiment and financial outlook for the company.

3 www.marketbeat.com, 12:08 AM
Quanterix Corporation's Q1 earnings call highlighted financial results, revenue growth, operational updates, Simoa platform advancements, and forward guidance amid neurology and oncology focus. Q1 earnings highlights show moderate financial performance and strategic updates influencing near-term operations but not transforming long-term trajectory.

6 May

4 , 8:00 AM
Lucent Diagnostics announced a collaboration with Tempus to integrate blood-based Alzheimer’s biomarker testing, powered by Quanterix’s Simoa technology, into clinical workflows for improved patient diagnosis and management. Tempus collaboration drives clinical adoption of Quanterix’s Alzheimer’s biomarkers, boosting revenue potential and market positioning.

3 Zacks, 5:25 PM
Quanterix Corporation (QTRX) reported a Q1 net loss and revenue below analyst estimates. Q1 loss and missed revenue estimates pressure short-term financial performance and investor sentiment.

3 Business Wire, 4:01 PM
Quanterix Corporation released financial results for the first quarter of 2026. Quarterly financial results affect key financial performance metrics and market sentiment with moderate influence.

2 May

4 Simply Wall St., 10:14 PM
Quanterix Corporation (QTRX) investment narrative shifts following latest fair value reset. Fair value reset alters Quanterix's core investment story, poised to significantly influence investor sentiment and market trajectory.

17 Apr

4 Business Wire, 8:33 AM
Quanterix Corporation's AidaBREAST™ multi-omic assay demonstrates spatial proteomics capabilities for clinical oncology applications. AidaBREAST™ advances spatial proteomics in oncology, enhancing Quanterix's product pipeline and competitive edge in clinical diagnostics.

15 Apr

4 , 8:33 AM
Quanterix Corporation debuted its Content Innovation Engine at AACR 2026, a new platform advancing research content generation and innovation. Debuting Content Innovation Engine at AACR 2026 launches a significant new product enhancing Quanterix's innovation leadership and market potential in life sciences.

3 Mar

4 transcript www.fool.com, 12:50 PM
Quanterix Corporation reported Q4 2025 revenue of $38.6 million, up 12% year-over-year, driven by Simoa platform growth in neurology and oncology. Full-year revenue reached $140 million. Company highlighted strong demand for HD-X instrument, record consumables sales, and expanded partnerships. 2026 guidance projects 15-20% revenue growth with improved profitability. Strong revenue growth, positive guidance, and platform expansion signal significant positive trajectory for financial performance and market position.

4 app.moby.co, 8:30 AM
Quanterix Corporation released its Q4 2025 earnings call summary, detailing financial results, operational updates, and forward guidance. Q4 earnings summaries disclose financial performance and guidance that significantly influence stock trajectory and investor sentiment.

4 GuruFocus.com, 12:01 AM
Quanterix Corp (QTRX) reported surging revenue in Q4 2025 earnings call amid key strategic shifts. Revenue surge and strategic shifts represent major developments likely to alter QTRX's financial trajectory and market position.

2 Mar

4 www.marketbeat.com, 5:32 PM
Quanterix Corporation (QTRX) released highlights from its Q4 earnings call, covering financial results, operational updates, and forward-looking guidance. Q4 earnings call highlights detail financial performance and strategic outlook, likely driving significant shifts in investor sentiment and stock trajectory.

4 Business Wire, 4:01 PM
Quanterix Corporation released financial results for the fourth quarter and full year 2025. Quarterly and annual financial results disclosure significantly affects investor sentiment, stock performance, and future strategic outlook.

4 Business Wire, 8:33 AM
Lucent Diagnostics partners with Life Line Screening to deliver advanced Quanterix-powered blood-based diagnostics to communities nationwide, expanding access to cutting-edge testing via mobile screening events. Partnership significantly broadens market reach for Quanterix diagnostics through nationwide screening network, enhancing revenue and adoption potential.

3 Zacks, 5:10 PM
Quanterix Corporation (QTRX) reported a fourth-quarter loss but beat revenue estimates. Q4 loss despite revenue beat affects financial performance and investor sentiment moderately.

14 Feb

4 Simply Wall St., 8:03 AM
Quanterix Corporation (NASDAQ: QTRX) has strong institutional backing, with 68% of its shares owned by institutional investors. This significant ownership indicates confidence in the company's potential and stability, which may positively influence its market performance and investor sentiment. High institutional ownership typically signals strong investor confidence and can lead to increased market stability and support for the company's growth.

4 Feb

4 Zacks, 12:57 PM
Quanterix Corporation has submitted a 510(k) application to the FDA for its multi-analyte blood test designed to aid in the diagnosis of Alzheimer's disease. This test aims to measure various biomarkers associated with the disease, potentially improving early detection and patient management. The submission represents a significant step in Quanterix's efforts to enhance diagnostic capabilities in neurology and could position the company favorably in the growing Alzheimer's diagnostics market. The FDA submission for a multi-analyte Alzheimer's blood test could significantly enhance Quanterix's market position and investor sentiment in a critical healthcare sector.

3 Feb

4 Business Wire, 8:33 AM
Quanterix Corporation has submitted a 510(k) application to the FDA for a multi-analyte algorithmic blood test aimed at detecting Alzheimer’s disease. This submission represents a significant step in the development of diagnostic tools for Alzheimer's, potentially enhancing early detection and treatment options. The FDA submission for a novel Alzheimer's detection test could significantly impact Quanterix's market position and investor sentiment.

21 Jan

4 Business Wire, 8:33 AM
Quanterix Corporation announced a significant study published in JAMA that underscores the prognostic value of a multi-analyte approach for blood-based Alzheimer’s risk profiling. This landmark research highlights the potential of Quanterix's technology to enhance early detection and risk assessment for Alzheimer’s disease, positioning the company at the forefront of advancements in neurodegenerative disease diagnostics. The study's findings could significantly enhance Quanterix's market position and drive future growth in Alzheimer's diagnostics.

8 Jan

4 Business Wire, 4:30 PM
Quanterix Corporation has appointed Everett Cunningham as President and CEO, effective January 19, 2026. Cunningham brings extensive experience in the life sciences sector, having held leadership roles at various companies. His appointment is expected to drive the company's strategic vision and growth initiatives. The appointment of a new CEO with significant industry experience is likely to have a substantial impact on the company's strategic direction and market performance.

22 Dec

4 Business Wire, 7:30 AM
Quanterix Corporation announced a groundbreaking study published in Nature that redefines the prevalence of Alzheimer’s disease neuropathology. The research highlights the importance of measuring biomarkers to better understand the disease's impact and prevalence. This study could lead to significant advancements in Alzheimer’s diagnostics and treatment strategies, positioning Quanterix at the forefront of neurological research. The study's findings could significantly influence Quanterix's strategic direction and enhance its competitive positioning in the Alzheimer's diagnostics market.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us